This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany



InCephalo is a preclinical stage biotech company focusing on protein engineering for local therapies for brain cancer and other CNS diseases. Its proprietary compartment-locked technology, also called C-Lock, retains locally applied drug at the injection site (tumour site) and once the drug leaves the diseased tissue they are rapidly degraded. Therefore significantly increasing efficacy and reducing potential side effects. The company has five (5) development programs. Its most advanced program, an IL-12, has received EMA ODD and is envisioned to go into the clinic by 2024. 

The company is led by a highly experienced management team. The CEO, Carlo, has co-founded and led three (3) biotech companies; the CSO, Johannes, is a preclinical expert for brain cancer diseases and the CMO, Lauren, is a highly experienced clinical trial expert having run more than 25 clinical trials in brain cancer.